XML 65 R53.htm IDEA: XBRL DOCUMENT
v3.22.4

Collaboration and License Agreements (Details) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2020 USD ($)
Collaboration and License Agreements [Abstract] |
Ipsen Revenue Recognized | $ 0.3
Ipsen product sales | $ 1.3

X
- Definition Collaboration and License Agreements [Abstract] + References No definition available. + Details
Name: | lxrx_CollaborationAndLicenseAgreementsAbstract
Namespace Prefix: | lxrx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period. + References No definition available. + Details
Name: | lxrx_IpsenRevenueRecognized
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of product sales to Ipsen. + References No definition available. + Details
Name: | lxrx_Ipsenproductsales
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration